DUBLIN–(BUSINESS WIRE)–The “Gene Delivery Systems Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering.
The gene delivery systems market studied was anticipated to grow with a CAGR of 7.3%, over the forecast period.
The significant factor attributing to the market’s growth is the rising incidence & prevalence of chronic diseases and increasing technological advancement in drug delivery. The increasing ongoing research and development in the field of genomics across the globe also drive the gene delivery systems market. Chronic diseases in developing countries are responsible for more fatalities. Some of the leading chronic diseases in developed countries such as the United States are cardiovascular diseases, infectious diseases, cancer, diabetes, and others.
As per the CDC (Centers for Disease Control and Prevention), six in ten adults in the United States have a chronic disease. As per the statistics, globally one in three adults has more than two or more chronic diseases, know as multiple chronic conditions. Gene delivery systems can help immensely in improving the human therapeutics used for the disease treatment. All these key factors are expected to boost the growth of gene delivery systems market over the forecast period.
Key Market Trends
Viral Gene Delivery Systems segment is Expected to Hold the Largest Share in the Gene Delivery Systems Market
- Dominate share is expected to be retained by the viral gene delivery systems owing to the attributes such as long-term expression, short term expression, and efficacy of therapeutic genes, and the rising advancement in technology over the last few years which has opened up many opportunities for growth in the healthcare industry. The increase in the prevalence of chronic diseases such as cancer and cardiovascular disorders is also aiding to the better market growth of gene delivery systems. (Read more…)
- The growing emphasis on governing and raising awareness about these treatments by governments in different countries has resulted in the rapid acceptance of these gene delivery systems worldwide. The rising support for R&D, along with the strong market position of major biopharmaceutical market players, has created a better entry passage for new market entrants.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to maintain its supremacy in the overall gene delivery systems market, throughout the forecast period. This is owing to factors such as the rising prevalence of chronic diseases in the region, technological advancement, and the domicile presence of major players in the region driving the growth and responsible for the dominance of the region. The well-established biotechnology, nanotechnology, and pharmaceutical industry coupled with rising awareness regarding advanced technologies for treatment of genetic and chronic diseases among the population in this region are also some of the key factors ensuring the dominance of the countries of this region.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic Diseases and Lifestyle Disorders
4.2.2 Technological Advancements in Research by Biopharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Reimbursement Issues
4.4 Porter’s Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Delivery Systems
5.1.1 Viral Gene Delivery Systems
5.1.1.1 Adenovirus Systems
5.1.1.2 Lentiviral Systems
5.1.1.3 Retroviral Systems
5.1.1.4 Others
5.1.2 Non Viral Gene Delivery
5.1.3 Combined Hybrid Delivery Systems
5.2 By Application
5.2.1 Oncology
5.2.2 Infectious Diseases
5.2.3 Cardiovascular Disorders
5.2.4 Diabetes
5.2.5 Pulmonary Disorders
5.2.6 Others
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Injectable
5.3.3 Nasal
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.2 Europe
5.4.3 Asia-Pacific
5.4.4 Middle-East and Africa
5.4.5 South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Novartis International AG
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Uniqure N.V.
6.1.6 Shenzhen SiBiono GeneTech Co.,Ltd
6.1.7 Bayer AG
6.1.8 Amgen Inc.
6.1.9 Shanghai Sunway Biotech Co., Ltd,
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/fvnbib
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900